Eversept Partners LP Buys 167,949 Shares of Liquidia Corporation $LQDA

Eversept Partners LP boosted its position in shares of Liquidia Corporation (NASDAQ:LQDA) by 33.0% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 677,392 shares of the company’s stock after buying an additional 167,949 shares during the quarter. Liquidia makes up approximately 1.3% of Eversept Partners LP’s holdings, making the stock its 20th largest holding. Eversept Partners LP’s holdings in Liquidia were worth $25,565,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of LQDA. Covestor Ltd increased its stake in shares of Liquidia by 41.9% in the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after buying an additional 359 shares during the period. PNC Financial Services Group Inc. boosted its holdings in Liquidia by 7.2% in the fourth quarter. PNC Financial Services Group Inc. now owns 6,304 shares of the company’s stock valued at $217,000 after acquiring an additional 422 shares during the last quarter. Quantinno Capital Management LP increased its position in Liquidia by 3.6% in the first quarter. Quantinno Capital Management LP now owns 17,165 shares of the company’s stock worth $648,000 after purchasing an additional 589 shares during the period. Northwestern Mutual Wealth Management Co. bought a new stake in Liquidia during the 4th quarter worth about $25,000. Finally, ProShare Advisors LLC lifted its position in Liquidia by 7.1% during the 4th quarter. ProShare Advisors LLC now owns 11,756 shares of the company’s stock valued at $405,000 after purchasing an additional 775 shares during the period. 64.54% of the stock is currently owned by institutional investors.

Liquidia Trading Down 2.1%

Shares of NASDAQ LQDA opened at $84.42 on Tuesday. The stock has a market cap of $7.51 billion, a price-to-earnings ratio of 603.04 and a beta of 0.55. Liquidia Corporation has a twelve month low of $16.82 and a twelve month high of $91.10. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18. The company’s fifty day moving average is $71.77 and its 200-day moving average is $50.58.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The firm had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. The firm’s quarterly revenue was up 4187.1% on a year-over-year basis. Equities research analysts predict that Liquidia Corporation will post 3.02 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on LQDA shares. Needham & Company LLC lifted their price target on shares of Liquidia from $54.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Stephens set a $130.00 price objective on shares of Liquidia in a report on Friday. Oppenheimer set a $75.00 price objective on shares of Liquidia in a research note on Friday, June 5th. Wells Fargo & Company lifted their target price on shares of Liquidia from $51.00 to $62.00 and gave the stock an “overweight” rating in a report on Tuesday, May 12th. Finally, Wall Street Zen cut shares of Liquidia from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 27th. Three analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $86.18.

Insider Buying and Selling

In related news, CFO Michael Kaseta sold 20,430 shares of the business’s stock in a transaction that occurred on Monday, July 13th. The stock was sold at an average price of $71.51, for a total value of $1,460,949.30. Following the completion of the transaction, the chief financial officer directly owned 345,805 shares in the company, valued at approximately $24,728,515.55. The trade was a 5.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Sarah Krepp sold 7,864 shares of the business’s stock in a transaction that occurred on Monday, July 13th. The shares were sold at an average price of $71.51, for a total value of $562,354.64. Following the completion of the transaction, the insider owned 117,178 shares of the company’s stock, valued at $8,379,398.78. This represents a 6.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 2,019,870 shares of company stock valued at $129,491,027. 25.60% of the stock is owned by company insiders.

Liquidia Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).